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Abstract
Association of a functional promoter polymorphism mapping to
the Fc receptor-like 3 (FCRL3) gene has recently been reported
and replicated with rheumatoid arthritis (RA) in Japanese
populations. The aim of this study was to investigate association
of the FCRL3 gene with RA in UK subjects. DNA was available
from 1065 patients with RA and 2073 population controls from
the UK. Four single nucleotide polymorphism (SNP) markers
(FCRL3-169*C/T (fclr3_3, rs7528684), fclr3_4 (rs11264799),
fclr3_5 (rs945635), fclr3_6 (rs3761959)) all previously
associated with RA in a Japanese population were genotyped in
761 RA samples and 484 controls. In the remaining samples,
only the putative disease causal polymorphism, FCRL3-169*C/
T, was tested. Genotyping was performed using either the
Sequenom MassArray iPlex platform or a 5' Allelic discrimination
assay (Taqman, ABI). Extensive linkage disequilibrium was
present across the promoter SNPs genotyped (r2 values = 0.60-
0.98). Allele frequencies did not differ between RA cases and
controls either for the putative disease causal polymorphism
(odds ratio FCRL3-169*C allele = 0.97 (0.87-1.07), p = 0.51)
or for the other SNPs tested. Similarly, no association was
detected with RA using haplotype analysis or when stratification
by shared epitope carriage or by presence of rheumatoid factor
was undertaken. This study was powered to detect an effect
size of 1.24 or greater for the FCRL3-169*C/T functional
promoter polymorphism but no evidence for association was
detected, suggesting that this gene will not have a substantial
effect in determining susceptibility to RA in populations of
Northern European descent.
Introduction
Rheumatoid arthritis (RA) is a complex disease, the hallmark of
which is synovial joint inflammation. The heritability of RA has
been estimated to be in the order of 60%, suggesting a sub-
stantial contribution from genetic factors [1]. The major sus-
ceptibility gene is the HLA DRB1 gene. Carriage of certain
alleles, collectively termed shared epitope alleles, confers a
twofold to threefold increased risk of RA.
Evidence for association with functional variants in two other
genes has been confirmed in multiple populations. Firstly, the
association of the PTPN22*R620W gene with RA in Cauca-
sians of Northern European descent has been widely repli-
cated (summarised in [2]). Interestingly, this disease causal
polymorphism is not present in the Japanese population, and
haplotype analysis of other polymorphisms mapping to the
gene has revealed no evidence for association [3]. Secondly,
association with a functional haplotype of the PADI4 gene has
been consistently demonstrated, mainly in Far Eastern popula-
tions [4-6].
An association with a further putative susceptibility gene has
recently been reported. Association with a functional promoter
variant of the Fc receptor-like 3 (FCRL3) gene has been
detected and replicated in Japanese patients with RA [7]. The
gene maps to 1q21, and linkage analysis studies in Japanese
RA families have previously highlighted this region as poten-
tially harbouring a susceptibility gene. Fine mapping under the
region of linkage identified association with RA of a promoter
polymorphism of the FCRL3 gene, and the association was
confirmed in an independent replication case–control cohort,
again of Japanese descent.
The FCRL3 gene has structural homology with the classical
FcγRs, and the protein product was shown to be expressed in
B cells, in secondary lymphoid organs and in aggregates ofPage 1 of 5
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demonstrated that the associated promoter polymorphism
(FCRL3-169*C/T) was shown to affect expression through
NF-κB binding. Furthermore, the number of FCRL3-169*C
susceptibility alleles correlated with autoantibody (rheumatoid
factor and cyclic citrullinated peptide antibodies) levels and
was higher in RA patients with two copies of shared epitope
alleles.
The association of a functional promoter polymorphism in a
strong candidate gene expressed in appropriate tissues has
therefore been detected and replicated with RA in a Japanese
population. It has already been noted, however, that striking
differences in associations have been found between Cauca-
sians of Northern European descent and Far Eastern popula-
tions for the non-HLA RA susceptibility genes identified to
date. Hence, the aim of the current study was to assess
whether the same FCRL3 genepolymorphisms were associ-
ated with RA in a UK population.
Patients and methods
Study design
A case–control (association) study was performed comparing
genotype frequencies of single nucleotide polymorphisms
(SNPs) mapping to the FCRL3 gene, previously associated
with RA in a Japanese population, with UK RA patients and
controls. Genotyping was performed in two stages: in the first
phase, association was tested with four SNPs in a subset of
the total cohort; while in the second stage, only the SNP iden-
tified as the probable disease causal polymorphism in the Jap-
anese study (FCRL3-169*C/T (fclr3_3, rs7528684)) was
genotyped in the remaining samples [7]. Comparisons with
controls were made in the case group as a whole and in sub-
groups stratified by carriage of the HLA DRB1 shared epitope
and PTPN22*620W alleles. Haplotypes were estimated using
the EM algorithm implemented in HelixTree software (Golden
Helix Inc., Bozeman, MT, USA) and frequencies were com-
pared between cases and controls.
Subjects
DNA was available from 1,065 cases with RA. All cases satis-
fied American College of Rheumatology 1987 classification
criteria for RA modified for genetic studies [8] and were
recruited as described previously [9]. Of these participants,
65.3% (690/1057) were female, 77.2% (782/1013) were
rheumatoid factor-positive, 79.7% (642/806) were erosive,
and 20.4% (149/729), 49.1% (358/729) and 30.5% (222/
729) patients carried zero, one or two copies of shared
epitope alleles, respectively.
Control subjects with no history of inflammatory arthritis were
recruited from blood donors and general practitioner registers
(n = 484) or from subjects recruited as part of the 1958 Birth
Cohort, a cohort comprising DNA samples from a randomly
selected subset of children born in England, Scotland, and
Wales in 1 week in March 1958 (approximately 17,000 live
births) who have been followed prospectively [10]. The Over-
sight Committee for the Biomedical Assessment of the British
1958 Birth Cohort Study provided access to DNA collected
from 2,064 individuals from the 1958 birth cohort randomly
distributed across the United Kingdom. Genotype data gener-
ated from the 64 non-White individuals included in the cohort
was not included in the analysis. Of the available samples,
genotyping was attempted in 1,600 and was successful in
1,589 in the current study. Of all the controls genotyped,
1,144/2,073 were female (55.2%). HLA DRB1 data were
available only on a subset but, of these, 50.4% (605/1200),
39.4% (473/1200) and 10.2% (122/1200) carried zero, one
or two copies of shared epitope alleles, respectively.
Ethical approval for the study was obtained and all participants
provided informed consent.
Polymorphisms selected
Four SNPs – FCRL3-169*C/T (fclr3_3, rs7528684), FCRL3-
169*C/T (fclr3_4, rs11264799), FCRL3-169*C/T (fclr3_5,
rs945635) and FCRL3-169*C/T (fclr3_6, rs3761959) – were
initially selected for investigation because they had all been
associated with RA in the Japanese population on single-point
analysis, because the SNPs formed a haplotype associated
with RA and because the most probable disease causal SNP
(FCRL3-169*C/T (fclr3_3, rs7528684)) was included [7].
Genotyping
Genotyping was performed mainly using the Sequenom Mas-
sArray platform according to the manufacturer's instructions
[11]. For one SNP, FCRL3-169*C/T (fclr3_3, rs7528684), a
subset of the samples were genotyped using a 5'-allelic dis-
crimination assay as described previously [9]. Duplicate sam-
ples and negative controls were included across the plates to
ensure accuracy of genotyping. In addition, for all the assays,
genotyping was confirmed in a subset of samples using the
Pyrosequencing genotyping method according to manufac-
turer's instructions [12].
Haplotype analysis
Haplotypes were estimated using the EM algorithm imple-
mented in HelixTree software (Golden Helix Inc.). Haplotypes
were also estimated using the PHASE program, which uses
the Markov Chain Monte Carlo method to estimate haplotypes
[13]. Missing genotypes were imputed and estimated haplo-
type frequencies compared between RA cases and controls.
Power
The study had 80% power to detect an odds ratio of 1.24 at
the 5% significance level, assuming a recessive model [7]. It
was powered to detect a smaller effect size than that originally
reported in the Japanese study (odds ratios of 2.15 and 1.3 for
the test cohort and replication cohort, respectively) as it isPage 2 of 5
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Results
Re-genotyping all SNPs in a subset of samples using the pyro-
sequencing platform revealed 100% concordance between
genotype calls made from different platforms. A subset of sam-
ples genotyped using the Sequenom and Taqman (ABI, War-
rington, UK) platforms for the FCRL3-169*C/T (fclr3_3,
rs7528684) SNP were also 100% concordant. Duplicate
samples across plates similarly showed no discrepant calls.
No deviation from Hardy–Weinberg expectations was
observed for any of the SNPs in either cases or controls.
Interim analysis after genotyping a subset of the total cohort
revealed that extensive linkage disequilibrium was present
across the four SNPs tested. Indeed, the D' value between all
the SNPs was 0.98 while the correlation between SNPs
FCRL3-169*C/T (fclr3_3, rs7528684), FCRL3-169*C/T
fclr3_5 (rs945635) and FCRL3-169*C/T fclr3_6
(rs3761959) was also 0.98 in this sample. The correlation
between these SNPs and FCRL3-169*C/T fclr3_4
(rs11264799) was 0.6 or greater, reflecting the difference in
allele frequency of this SNP compared with the others. Hence,
genotyping of all four SNPs was unnecessary and, in the
remaining samples, only the putative disease causal polymor-
phism was genotyped.
None of the SNPs tested was associated with RA using sin-
gle-point analysis methods (Table 1). By contrast to the find-
ings in the Japanese study, we found no correlation of FCRL3-
169*C susceptibility allele frequency with shared epitope
allele carriage or with the presence of rheumatoid factor (Table
1). Stratification based on carriage or absence of shared
epitope alleles (data not shown), on carriage of the
PTPN22*620W gene susceptibility variant (odds ratio
FCRL3-169*C allele = 1.12 (95% confidence interval 0.87–
1.44), P = 0.37), on gender and on age at onset of RA similarly
Table 1
Genotype frequencies of Fc receptor-like 3(FCRL3) single nucleotide polymorphisms in rheumatoid arthritis cases, in controls and 
in subgroups
Single nucleotide polymorphism Controls Cases Two-copy shared epitope allelesb Rheumatoid factor-positive a, c
Controls Cases
FCRL3-169*C/T (fclr3_3, rs7528684)
T/T 595 (28.7) 324 (30.4) 45 (36.9) 71 (32.0) 324 (30.4)
C/T 1055 (50.9) 524 (49.2) 52 (42.6) 103 (46.4) 524 (49.2)
C/C 423 (20.4) 217 (20.4) 25 (20.5) 48 (21.6) 217 (20.4)
P value 0.57 0.69 0.57
FCRL3-169*C/T (fclr3_4, rs11264799)
1/1 258 (53.3) 404 (53.1) 13 (50.0) 132 (52.6) 404 (53.1)
1/2 190 (39.3) 296 (38.9) 10 (38.5) 95 (37.8) 296 (38.9)
2/2 36 (7.4) 61 (8.0) 3 (11.5) 24 (9.6) 61 (8.0)
P value 0.93 0.94 0.93
FCRL3-169*C/T (fclr3_5, rs945635)
1/1 123 (27.9) 209 (28.4) 9 (36.0) 64 (27.3) 209 (28.4)
1/2 200 (45.3) 362 (49.3) 12 (48.0) 116 (49.6) 362 (49.3)
2/2 118 (26.8) 164 (22.3) 4 (16.0) 54 (23.1) 164 (22.3)
P value 0.46 0.57 0.46
FCRL3-169*C/T (fclr3_6, rs3761959)
1/1 124 (26.3) 209 (27.8) 8 (30.8) 65 (27.1) 209 (27.8)
1/2 220 (46.7) 370 (49.3) 12 (46.1) 120 (50.0) 370 (49.3)
2/2 127 (27.0) 172 (22.9) 6 (23.1) 55 (22.9) 172 (22.9)
P value 0.28 0.91 0.28
Data presented as n (%). aComparison group = all controls. bSubgroup stratified by two copies of shared epitope alleles. cSubgroup stratified by 
the presence of rheumatoid factor (measured cumulatively).Page 3 of 5
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Haplotype analysis
Of the 16 possible estimated haplotypes, only three existed at
a population frequency greater than 1%. Estimated frequen-
cies were similar whether estimated using the EM algorithm in
HelixTree software (Golden Helix Inc.) or the Markov Chain
Monte Carlo algorithm in the PHASE program [13]. No differ-
ence in the distribution of these haplotypes was noted
between cases and controls (Table 2).
Discussion
Association of a promoter polymorphism mapping to the
FCRL3 gene with RA has recently been reported in a Japa-
nese population [7]. The gene is likely to play a role in immune
regulation, and functional data showed that the associated
polymorphism controls the levels of gene expression. The
association was replicated in the same study in another cohort
of RA patients, with systemic lupus erythematosus and autoim-
mune thyroid disease. Furthermore, association has since
been replicated by a separate group of investigators in an
independent cohort of RA patients and controls from Japan
[14]. Hence, strong evidence exists to support the hypothesis
that variation within the gene may be disease causal. In this
well-powered study, however, we have failed to demonstrate a
similar association with RA in a UK population.
Our result may represent a false-negative finding, but this is
unlikely for several reasons. Firstly, we had 100% power to
detect a similar effect size to that reported in the original study
(effect size in test group, 2.15) and 90% power to detect the
effect size of 1.3 reported in their replication cohort [7]. Sec-
ondly, false-negative findings can also occur as a result of pop-
ulation stratification, but our control allele frequencies are
similar to those reported previously in populations of Northern
European descent and no difference in allele frequencies was
observed between control or case samples from different
regions of the United Kingdom (data not shown). Finally, pre-
vious studies from US and Spanish populations have also
failed to demonstrate association with RA at this locus
[15,16].
It seems probable, then, that the association of this polymor-
phism with RA may be population specific. This is analogous
to the association of the PTPN22*R620W polymorphism with
RA in European, Northern and Southern American populations
but not in Far Eastern populations (summarised in [2]). In this
case, the population specificity arises from the fact that the
polymorphism is common in European and Northern American
populations (approximately 10% minor allele frequency) but
very rare in Japan. For the FCRL3 gene, however, the putative
disease causal allele is common in both the UK and Japanese
cohorts (45% and 35% minor allele frequency, respectively)
so this cannot explain the population differences found. Simi-
larly, the same haplotypes exist, albeit at slightly different fre-
quencies.
Association of the PADI4 gene with RA also shows variation
between populations and, like the FCRL3-169*C/T gene pol-
ymorphism, the susceptibility haplotype is common in all pop-
ulations. A functional haplotype of the PADI4 gene has been
consistently associated with RA in Far Eastern populations [4-
6]. While most studies in patients of Northern European
descent have failed to demonstrate any association [9,17,18],
one study in a US population did recently report that this gene
may have a very small effect [19]. This finding has yet to be
confirmed but, if it is, it may be argued that the effect size for
the FCRL3 gene may also simply be much smaller in popula-
tions of Northern European descent, possibly reflecting differ-
ences in exposure to environmental susceptibility factors
between populations. In support of this, a study in the UK pop-
ulation has replicated association of the FCRL3-169*C/T
gene polymorphism with Graves' disease but with a smaller
effect size [20]. Our study was sufficiently powered, however,
to detect an effect size of 1.24. Indeed, by combining our data
with those reported from a North American population, an
effect size of 1.18 can be excluded with 80% power [15].
The differences in the association of disease in different pop-
ulations highlights the importance of accounting for ethnic ori-
gin when performing association studies, particularly in
populations where considerable ethnic mixing may have
occurred, such as that found in the United States.
Table 2
Estimated haplotype frequency distributions in cases and controls
Haplotype Controls (%) Cases (%) Overall comparison (P value)
T, G, G, G 53.1 52.7 0.97
C, A, C, Aa 25.2 27.2
C, G, C, A 20.6 18.5
aHaplotype associated with rheumatoid arthritis in a Japanese population.Page 4 of 5
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The presented findings do not support a major role for the
FCRL3 gene in determining susceptibility to RA in populations
of Northern European descent.
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